They restore, amplify, or redirect those signals
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
Recent evidence suggests that intentional weight loss in older adults with overweight and obesity is effective and safe, hence a diminishing reluctance to use AOMs in this more vulnerable population
Compounded semaglutide and tirzepatide are not FDA-approved medications
We break this down in more detail in our guide on stopping GLP-1 injections before surgery
Potential laboratory applications include investigations into: Cellular Signaling Researchers study how peptide interactions influence communication between cells and intracellular signaling pathways